Citigroup Global Markets Australia Acquires 5.3% Stake, Becoming Major Shareholder in Cochlear Limited

Cochlear Limited: A Global Leader in Medical Devices

Cochlear Limited, an Australian ASX-listed medical device manufacturer, develops, produces, and markets implantable hearing and neuroscience solutions worldwide. The company serves patients and healthcare systems across continents through proprietary implant technologies and related treatments. Its business model focuses on innovative medical devices addressing critical unmet needs in hearing restoration and neurological disorders, establishing Cochlear as a key player in the advanced medical technology sector with strong research and development capabilities.

The company’s operations encompass product development, clinical validation, regulatory approvals, and ongoing patient support. Cochlear’s strong market position is supported by extensive intellectual property, clinical evidence, and global healthcare partnerships. Revenue streams derive from initial implant sales and continued sales of processors, accessories, and services supporting a global installed user base. Understanding Cochlear’s shareholder composition offers insight into institutional confidence in its growth prospects within the competitive medical device industry.

Citigroup’s Diverse Entity Investment in Cochlear

The substantial shareholding notification reveals Citigroup’s 5.2955% stake was accumulated across multiple related entities operating in various jurisdictions. The largest holding is 1,494,214 shares by Citibank, N.A. Sydney Branch, acting as agent lender under securities lending agreements, enabling voting rights on borrowed shares with an obligation to return them under standard terms. Another significant holding is 1,044,838 shares by Citigroup Global Markets Limited, acquired through securities lending and market transactions.

Additional holdings include 714,408 shares by Citigroup Global Markets Australia Pty Limited, 205,661 shares by Citibank, N.A., and 4,035 shares by Citigroup Global Markets Inc, plus a minor 14-share holding by Citicorp Trust Delaware National Association. This distribution across entities reflects Citigroup’s operational structure, where regional and functional units participate in securities transactions. All entities are associates within the Citigroup group, illustrating a common institutional investment approach involving multiple operating entities for operational, tax, and risk management purposes.

Securities Lending as a Key Component of the Stake

A substantial portion of Citigroup’s Cochlear shares are held under securities lending agreements governed by AMSLA, GMSLA, and MSLA frameworks. Citibank, N.A. Sydney Branch holds 1,494,214 shares as agent lender with an obligation to return them. Citigroup Global Markets Australia and Citigroup Global Markets Limited also hold significant shares under similar lending arrangements.

These lending agreements grant voting rights to the borrower, allowing Citigroup entities to exercise votes on borrowed shares without restrictions. Both lenders and borrowers retain rights to recall or return securities early under standard terms. The loans have no fixed return date, indicating open-ended arrangements adjustable to the parties’ needs. This securities lending structure is typical in institutional investments, providing liquidity and market exposure flexibility.

Acquisition Timeline and Market Transaction Details

Citigroup’s stake was accumulated over various dates, with substantial holder status triggered on 23 July 2026. The notification covers securities acquired within the preceding four months, with acquisition dates and prices described as "various". This reflects gradual institutional accumulation through ongoing market participation rather than a single acquisition or controlling intent.

Shares acquired via ordinary stock market transactions were obtained under standard terms without special provisions. Citibank, N.A. holds 205,661 shares from such transactions, Citigroup Global Markets Australia holds 714,408 shares similarly acquired, Citigroup Global Markets Inc holds 4,035 shares, and Citicorp Trust Delaware National Association holds 14 shares. This pattern indicates routine institutional investment activity across multiple entities rather than a strategic placement.

Registered Holder and Nominee Structures

Cochlear shares held by Citigroup entities are registered through nominee arrangements, primarily Citicorp Nominees Pty Limited, and for Citibank, N.A. Sydney Branch holdings, through various registered holders. Citicorp Nominees Pty Limited is registered for 205,661 shares beneficially owned by Citibank, N.A.; 714,408 shares by Citigroup Global Markets Australia Pty Limited; 4,035 shares by Citigroup Global Markets Inc; 1,044,838 shares by Citigroup Global Markets Limited; and 14 shares by Citicorp Trust Delaware National Association.

This nominee structure facilitates streamlined administration, efficient transaction settlement, and potential tax and regulatory management across jurisdictions. Such arrangements are standard in global financial markets and fully disclosed via Form 603 notifications, ensuring transparency of beneficial ownership despite nominee layers.

Global Footprint of Citigroup Entities Holding Cochlear Shares

Citigroup’s Cochlear shareholding involves entities across Australia, the United States, and the United Kingdom. Citibank, N.A. Sydney Branch and Citigroup Global Markets Australia Pty Limited operate from Two Park, 2 Park Street, Sydney NSW 2000, Australia. Citigroup Global Markets Inc is based at 388 Greenwich Street, New York, NY 10013, USA. Citigroup Global Markets Limited operates from Citigroup Centre, Canary Wharf, 33 Canada Square, London, E14 5LB, UK. Citicorp Trust Delaware National Association, holding 14 shares, is located at 20 Montchanin Road, Suite 180, Greenville, Delaware 19807, USA.

This geographic distribution reflects Citigroup’s global institutional investment approach, optimising regulatory compliance, operational efficiency, and market access. The coordinated international structure underscores that Citigroup’s Cochlear investment is a globally managed position rather than a local entity initiative, illustrating how major financial institutions engage in Australian equity markets through their worldwide networks.

Impact on Cochlear Shareholders and Market Outlook

Citigroup Global Markets Australia’s emergence as a substantial shareholder with 5.2955% voting power signals significant institutional confidence in Cochlear Limited. Holding over 3.4 million shares demonstrates a major capital commitment and belief in Cochlear’s medium- to long-term growth potential in the medical device sector. Investors may interpret this as an endorsement of Cochlear’s market position and strategic direction.

The securities lending component adds complexity, as voting rights are maintained on borrowed shares, but early recall provisions mean the shareholding composition could change if lending agreements end. This standard institutional practice provides liquidity and flexibility but means the 5.2955% stake represents a snapshot subject to market dynamics. Overall, the notification confirms ongoing institutional interest in Cochlear’s equity through conventional market mechanisms.

Regulatory Compliance and Form 603 Disclosure

The notification was made via Form 603 under section 671B of the Corporations Act, mandating disclosure when voting power in an Australian listed company reaches or exceeds 5%. The requirement applies regardless of acquisition method and includes holdings through securities lending and derivative interests.

Form 603 demands detailed disclosure of relevant interests, beneficial owners, registered holders, security classes, consideration paid, and associates. Citigroup’s filing complies fully by detailing multi-entity holdings, securities lending arrangements, and associate relationships. This regulatory framework ensures transparent, timely market information on substantial shareholdings, supporting informed investor and management decisions.

Contact Information for Substantial Shareholding Inquiries

For inquiries related to this substantial shareholding, Cochlear investors and stakeholders may contact Briana Mandile at Citigroup Global Markets Australia Pty Limited by phone at +61 2 8225 4066. This contact serves as the primary liaison for communications regarding the disclosure and related matters, reflecting best practices in regulatory transparency.

The Form 603 was lodged on 27 July 2026, complying with the two-business-day requirement following Citigroup’s attainment of substantial holder status on 23 July 2026. This timely disclosure aligns with regulatory obligations, ensuring market participants receive prompt notification of significant shareholder changes. The structured Form 603 process balances transparency with operational efficiency, enabling active institutional participation in equity markets while maintaining disclosure standards.